Home Alzheimer’s Disease Study Suggests Oxaliplatin-Fluoropyrimidine Combo To Be Standard-of-Care Adjuvant Treatment for Stage III...

Study Suggests Oxaliplatin-Fluoropyrimidine Combo To Be Standard-of-Care Adjuvant Treatment for Stage III MSI/dMMR Colon Cancer

A meta-analysis of individual patient data from the ACCENT database demonstrated that the combination of oxaliplatin plus fluoropyrimidine (FP) should be considered standard-of-care adjuvant therapy for patients with microsatellite instability or mismatch repair deficient (MSI/dMMR) stage III colon cancer.1

The study, published in the Journal of Clinical Oncology, also indicated that patients with colon cancer and MSI experienced better outcomes in the N1 group when compared with those with microsatellite stable (MSS) disease; however, both groups saw similar survival in the N2 group. Given these findings, the investigators suggested that N stage should be a stratification parameter in future trials dedicated to the MSI/dMMR population.

“As the current work is the largest ever published on adjuvant FP for patients with MSI stage III [colon cancer], it suggests that FP alone should not…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Women of Minority Race/Ethnicity, Lower Socioeconomic Status Experience Lower Digital Breast Tomosynthesis Access

A cross-sectional study of digital breast tomosynthesis (DBT) screening published in JAMA Network Open indicated that women of minority race/ethnicity and lower socioeconomic status...

Recent Comments